Home Compare EHC vs HIK.L
Stock Comparison · Single-driver result

Encompass Health vs Hikma Pharmaceuticals: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Hikma Pharmaceuticals carrying a narrow edge on profitability. Encompass Health still has the edge on stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Profitability is the clearest driver, while stability keeps the result from looking one-way.

Trajectory Similarity
0.76
Similar
Peer-set rank: #2
within Encompass Health Corporation's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

The pair sits on a clearly comparable long-term path, though it is not a near-twin match.

The clearest structural overlap shows up in margin consistency and capital structure.

Similarity drivers
margin consistencycapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
EHC
Encompass Health Corporation
50
Peer-Score
Signal qualityMedium
vs
HIK.L
Hikma Pharmaceuticals PLC
53
Peer-Score
Signal qualityMedium

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in profitability.

Dimension spread: EHC vs HIK.L Profitability 18 39 Stability 51 32 Valuation 84 87 Growth 48 44 EHC HIK.L
Gap Ranking
#1 Profitability +21
#2 Stability +19
#3 Growth +4
#4 Valuation +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for EHC and HIK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer EHCHIK.L Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against Encompass Health Corporation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both sit in the weaker half on profitability, with Hikma Pharmaceuticals PLC still coming out ahead.
Stability
Encompass Health Corporation sits in the stronger part of the group on stability, while Hikma Pharmaceuticals PLC is closer to mid-pack.
Profitability — Dominant Gap
EHC
18
HIK.L
39
Gap+21in favour of HIK.L

The clearest distance comes from a stronger profitability profile.

What keeps the gap from being one-sided

Stability still tilts materially toward Encompass Health Corporation, which stops the result from looking dominant across the whole profile.

What this means for the comparison

Profitability is the clearest driver of the lead, with stability adding further support — though stability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the EHC vs HIK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-stability comparisons

Explore how EHC and HIK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.